PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA (GASTFOX)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03006432 |
|
Recruitment Status :
Recruiting
First Posted : December 30, 2016
Last Update Posted : March 24, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Gastric cancer is the fourth commonest cancer and the second largest cause of mortality from cancer. Surgical resection of localised forms of gastric cancer offers the only chance of a cure. The vast majority of patients, however, present with advanced disease from the outset (locally advanced or metastatic) or recurrent after resection of a localised form.
For metastatic or locally advanced stages of gastric or gastro-oesophageal junction adenocarcinoma, the combination of 2 chemotherapy drugs (dual therapy) as compared with monotherapy or no chemotherapy, makes it possible to improve the tumour response and patient survival. Dual therapy comprising cisplatin + fluoropyrimidine (CF protocol) is considered as one of the first-line chemotherapy treatment standards.
The addition of docetaxel to the CF regime (referred to as the DCF protocol) has made it possible to improve the tumour response rate, the time to tumour progression and overall survival in a randomised phase III trial. This improvement in treatment efficacy was achieved, however, at the expense of a significant increase in grade 3-4 toxicity, including diarrhoea , neutropenia, and neutropenia with complications. Although DCF is considered as a therapeutic standard for advanced forms of gastric cancer, its use is limited in clinical practice due to its high toxicity.
Oxaliplatin has shown its usefulness in treatment of oesophagogastric cancer, with an efficacy at least equal to that of cisplatin. Peripheral sensory neuropathy was less common in the 5FU-cisplatin arm. In terms of treatment efficacy, 5FU-oxaliplatin versus 5FU-cisplatin was associated with a non-significant improvement in median progression free survival rates, and overall survival.
All these data thus suggest that 5FU-oxaliplatin is at least as efficacious and is better tolerated than 5FU-cisplatin, and also that docetaxel-5FU-cisplatin is more efficacious than 5FU-cisplatin, with limited use due to its high toxicity. In the logical continuation of development of chemotherapy protocols for metastatic gastric cancer, the question therefore arises of the usefulness of adding docetaxel to 5FU-oxaliplatin, in terms of efficacy and also tolerance.
In France, chemotherapy with FOLFOX is used extensively as a first line of treatment in advanced gastric cancer, but with progression-free survival and median survival rates that are still too low, and a poor response rate. The use of docetaxel at a dose of 50 mg/m2 every 2 weeks in combination with FOLFOX (TFOX protocol) has shown very interesting results in phase II studies in terms of efficacy and tolerability, and these are worth confirming through a phase III randomised trial. In fact, if these results are confirmed in phase III, TFOX could become the new first-line therapeutic standard for advanced gastric cancer, while limiting toxicity and preserving patients' quality of life, and could become the reference treatment to accompany the targeted therapies currently being developed for this disease.
The primary objective of this randomised phase III trial is to compare the progression-free survival on dual therapy with 5FU-oxaliplatin (FOLFOX protocol) with triple therapy with 5FU-oxaliplatin-docetaxel (TFOX protocol) in treatment of advanced forms of gastric or oesophagogastric junction adenocarcinoma. The secondary objectives are overall survival, the tumour response rate, toxicity, quality of life and the therapeutic index, defined as the ratio between the median progression-free survival and the febrile neutropenia rate.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| OESOPHAGO-GASTRIC CARCINOMA | Drug: Oxaliplatin Drug: 5Fluorouracil bolus Drug: 5Fluorouracil continu Drug: Docetaxel Drug: Folinic Acid | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 506 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES |
| Study Start Date : | December 2016 |
| Estimated Primary Completion Date : | December 2022 |
| Estimated Study Completion Date : | December 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: FOLFOX
Cycles every 15 days until progression desease
|
Drug: Oxaliplatin Drug: 5Fluorouracil bolus Drug: 5Fluorouracil continu Drug: Folinic Acid |
|
Experimental: TFOX
Cycles every 15 days until progression desease
|
Drug: Oxaliplatin Drug: 5Fluorouracil continu Drug: Docetaxel Drug: Folinic Acid |
- progression-free survival [ Time Frame: 12 months after laste randomisation ]
- Overall survival Toxicity events (adverse events) according to NCI-CTC v4.0 [ Time Frame: 12 months after laste randomisation ]
- Objective response rate [ Time Frame: 12 months after laste randomisation ]
- Toxicity events according to NCI-CTC v4.0 [ Time Frame: 12 months after laste randomisation ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Gastric or gastro-oesophageal junction adenocarcinoma (all Siewert), histologically proven (on primary tumour or metastatic lesion),
- HER2 negative (positive HER2 status is defined by a positive IHC test of 3+ or IHC of 2+ with positive FISH)
- Metastatic or non-resectable (locally advanced) disease
- Disease measurable according to RECIST v1.1 criteria (at least one measurable lesion)
- No major surgical procedure during the 4 weeks prior to randomisation:
- Patient eligible for a 1st line of chemotherapy based on 5FU, folinic acid and oxaliplatin (FOLFOX) with or without docetaxel (TFOX)
- WHO: 0-1
- Age ≥ 18
- BMI > 18
- Life expectancy > 3 months
- PNN > 1500/mm3, platelets > 100,000/mm3, Hb > 10 g/dL
- AST, ALT ≤ 3.5 times the UNL, alkaline phosphatase < 6 times the UNL
- Bilirubin ≤ 1.5 times the UNL,
- Creatinine clearance according to Cockcroft and Gault formula > 50 mL/min
- Women of childbearing age must have a negative pregnancy test (β HCG) before starting treatment
- Women of childbearing age and men (who are in a sexual relationship with women of childbearing age) must agree to use effective contraception without interruption for the duration of the treatment and for 6 months after administration of the last dose of treatment
- Patient affiliated to a social security scheme
- Patient information and signature of informed consent form
Exclusion Criteria:
- Presence of cerebral or meningeal metastases
- Presence of > grade 2 neuropathy according to NCIC-CTC 4.0
- Known DPD deficiency
- QT/QTc interval > 450 msec for men and > 470 msec for women
- K+ < LNL, Mg2+ < LNL, Ca2+ < LNL
- Any known specific contraindication or allergy to the treatments used in the study (cf RCP Appendix 7)
- Chemotherapy or radio-chemotherapy in an adjuvant situation finished less than 12 months ago
- Prior chemotherapy including oxaliplatin (except for adjuvant chemotherapy)
- Prior chemotherapy including docetaxel
- Any progressive pathology not stabilised over the past 6 months: liver impairment, renal impairment, respiratory or cardiac failure
- HIV+ patients
- Radiotherapy during the 4 weeks prior to randomisation
- Other concomitant cancer or a history of cancer during the previous 5 years, with the exception of carcinoma in situ of the cervix or basal cell carcinoma or epidermoid cell carcinoma of the skin which is considered to be cured
- Patient already included in another clinical trial involving an experimental drug
- Pregnant or breastfeeding woman
- Persons in custody or under wardship
- Impossibility of undergoing medical monitoring during the trial for geographical, social or psychological reasons
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03006432
| Contact: Marie MOREAU | +33 (0)380393404 | marie.moreau@u-bourgogne.fr |
Show 98 study locations
| Study Chair: | Aziz ZAANAN | HEGP, Paris |
| Responsible Party: | Federation Francophone de Cancerologie Digestive |
| ClinicalTrials.gov Identifier: | NCT03006432 |
| Other Study ID Numbers: |
PRODIGE 51 |
| First Posted: | December 30, 2016 Key Record Dates |
| Last Update Posted: | March 24, 2022 |
| Last Verified: | March 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
OESOPHAGO-GASTRIC CARCINOMA |
|
Carcinoma Stomach Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Leucovorin Folic Acid Docetaxel Fluorouracil |
Oxaliplatin Levoleucovorin Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antidotes Protective Agents Vitamin B Complex |